HAPPY X” MAS
1.Canada has become the second country after the US to approve Moderna's coronavirus vaccine.
2.New(Artificial Intelligence) AI COVID-19 screening test, named CURIAL AI, which uses routinely collected clinical data for patients presenting to hospital could allow exclusion of patients who do not have COVID-19.
3.Newer IT TOOLS
New applications range from dashboards connecting cloud-based electronic health records to identify trends in high-risk patients and testing activity, to the establishment of data hubs facilitating near-real-time data aggregation and analysis to inform decisions around resources and clinical care associated with COVID-19 across hospital groupings. There are also many examples of COVID-19 portals that give overviews of national and international trends, hosted on cloud services, which are currently in development.
4.In UK Statutory Public Enquiry being demanded to investigate lapses in Covid19 response and to take immediate corrective measures
5.One in five people have symptoms that persist after 5 weeks, and one in ten have symptoms for 12 weeks or longer after acute COVID-19 infection as reported in a study.
6.Study found up to 66% of people with long COVID have organ damage and 25% have damage to multiple organs.
7.Conditions experienced by members of the UK doctors under LONG COVID are;
• Myocarditis or pericarditis
• Microvascular angina
• Cardiac arrhythmias, including atrial flutter and atrial fibrillation
• Dysautonomia, including postural orthostatic tachycardia syndrome
• Mast cell activation syndrome
• Interstitial lung disease
• Thromboembolic disease (pulmonary emboli or cerebral venous thrombosis) • Myelopathy, neuropathy, and neurocognitive disorders
• Renal impairment
• New-onset diabetes and thyroiditis
• Hepatitis and abnormal liver enzymes
• New-onset allergies and anaphylaxis
• Dysphonia
8.Negative binomial regression revealed that when adjusted for age, gender, and serology of index case, the incidence of COVID-19 among close contacts of a symptomatic index case was 3·85 times higher than for close contacts of an asymptomatic index case (95% CI 2·06–7·19).
9.The unknowns of how the vaccine affects transmission makes the possibility of achieving herd immunity through vaccination uncertain
10.EU, the UK, the USA, and Canada have already made deals with manufacturers to buy more than 50% of the doses expected to be available in 2021, despite these countries representing only 14% of the global population.
11.Speculatively, angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), both of which block the renin–angiotensin system (RAS), might affect people’s susceptibility to COVID-19 and worsen its severity.
12.The first Covid-19 shots have been given to more than 2.7 million people in six countries
13.Defective immune responses distinguish severe COVID-19 from moderate disease
•Monocyte antigen presentation pathway gene expression is lower in severe COVID-19
•Lymphocyte cytotoxicity pathways are reduced, and B cell activation is blunted
•Interferon signaling is elevated in lymphocytes but diminished in monocytes
14.Critically ill COVID-19 patients, but not those with mild symptoms, found to have high levels of afucosylated IgG antibodies against SARS-CoV-2, amplifying pro-inflammatory cytokine release and acute phase responses. Thus, antibody glycosylation plays a critical role in immune responses to enveloped viruses, including COVID-19.
15.Patients with severe asthma using biologic therapy showed to have a more severe course of COVID-19 compared to the general population. This may be due to co-morbidities, the severity of asthmatic airway inflammation, the use of biologics, or a combination of these.
16.Bioflavonoids are potential antiviral secondary metabolites.Mulberroside, Glycyrrhizic acid and Amentoflavone may hold promise in COVID-19 therapy.
17. Decreased NO level and bioavailability has been observed in patients with COVID-19.
• SARS-CoV-2 infection may cause NO dysfunction in cells and tissue via four pathways.
• Inhaled NO might participate in multiple stages of COVID-19 prevention or therapy
18.Pseudo-chilblains are the most common COVID-19 skin manifestation in Europe and the United States, but there is only one reported case from Asian populations. Additionally, patients with vaso-occlusive lesions are more likely than those with pseudo-chilblains to be admitted to the intensive care unit and to die.
19.Tramadol has anti-inflammatory, hypocogulatory, cardioprotective, antioxidant, antitussive, analgesic, antidepressant, and bactericidal effect. In conclusion, tramadol with its multiple mechanisms of action could be an effective therapeutic option for COVID-19 patients
20.IFNγ T?CoV?Spot assay is a reliable method to explore specific T cells in large cohorts of patients. This test may become a useful tool to assess the long?lived memory T?cell response after vaccination.
21.Income inequality, prevalence of obesity and diabetes, and concentration of fine particulate matter (PM 2.5) are strongly positively associated to confirmed cases and deaths regardless of lockdown.
22.MechBayes model performs significantly better than the classical SEIR model for Covid19 mortality forecast.
• Thanks for Happy Reading
• With regards
• Dr Dharmesh Lal(dharmeshlal@yahoo.co.in)
• DNB,MD,DHA,MBBS
Kindly share widely to all your contacts having potential to benefit policy makers,clinicians, patients, community and research activities.(already being shared further by more than 5000 primary recipients onwards through their WA groups to approximately 500000 readers in more than 100 countries)
